Longitudinal 18F-PBR06 (TSPO) and Volumetric MR Imaging as Pharmacodynamic Endpoints for MSA – Ongoing Investigator Sponsored Trial of Verdiperstat
Objective: In multiple system atrophy (MSA) patients to: 1) evaluate 18F-PBR06 positron emission tomography (PET) for longitudinal assessment of 18-kilodalton-translocator protein (TSPO) binding; 2) assess…Cerebellar tDCS for multiple system atrophy cerebellar: Double blinded, randomized, sham-control, cross-over study
Objective: The aim of study is to investigate an effect of a transcranial direct current stimulation (tDCS) on the primary motor cortex (M1) and cerebellum…Emotional, logistical and ethical aspects of voluntarily stopping eating and drinking in patients with movement disorders
Objective: We present two patients with atypical parkinsonism who chose to die by voluntarily stopping eating and drinking (VSED) to highlight the unique support and care needs associated…Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials
Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…Non-invasive imaging markers of iron accumulation in Multiple System Atrophy
Objective: To define the localization and extent of iron accumulation in multiple system atrophy (MSA). Background: Elevated iron concentration in the basal ganglia has been…Effect of repetitive transcranial magnetic stimulation with intensive physical therapy in cerebellar ataxia: A pilot study
Objective: The present study investigated the efficacy and safety of combination treatment of repetitive transcranial magnetic stimulation (rTMS) and physical therapy (PT) in patients with…Inosine 5′-Monophosphate to Raise the Serum Uric Acid Level in Patients with Multiple System Atrophy (IMPROVE-MSA study): A Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Assigned Clinical Trial
Objective: To investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'-monophosphate (IMP) in multiple system atrophy (MSA). Background: Converging…Body Weight-Supported Treadmill Training Improves Walking Function in Multiple System Atrophy: A Case Report
Objective: Multiple system atrophy (MSA) is a rapidly progressive synucleinopathy involving autonomic dysfunction and impaired mobility. MSA has been further sub-classified into two phenotypes: parkinsonian…Treatment of Neurogenic Orthostatic Hypotension (nOH) in Multiple System Atrophy (MSA) with a wearable Pneumatic Compression Garment utilising Soft Robotics
Objective: To use a novel Pneumatic Garment device for treatment of nOH in MSA. Background: nOH is present in 66-90% of patients with MSA and…Cardiac Safety of PBT434, an Inhibitor of Alpha-Synuclein Aggregation for the Treatment of Multiple System Atrophy (MSA)
Objective: Evaluate potential cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from a Phase 1 study of PBT434…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »